Healthcare Business

Menlo Therapeutics Closes in on IPO

Menlo Therapeutics has registered an amended S-1 filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company plans on pricing its 5.67 million ...
Read Full Story »

Credit Suisse Outlines Top Biotech M&A Targets and Catalyst Stocks for 2018

Get ready for more mergers and acquisitions in biotech and in emerging pharmaceuticals in 2018. This theme is believed by many investors, and now Credit Suisse is touting that tax ...
Read Full Story »

Investors Cheer BeiGene’s Secondary Offering

Shares of BeiGene Ltd. (NASDAQ: BGNE) saw a handy gain on Thursday after the company announced that it would be conducting a secondary offering. Usually, companies conducting these offerings see ...
Read Full Story »

Exelixis Slides Despite Positive Late-Stage Results

Shares of Exelixis Inc. (NASDAQ: EXEL) slipped on Wednesday after the company reported results from its late-stage trial for advanced hepatocellular carcinoma (HCC). Specifically, this was a pivotal Phase 3 ...
Read Full Story »

ARMO Announces Potential Pricing for IPO

ARMO BioSciences has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price its 6.67 million ...
Read Full Story »

Why Juno Therapeutics Is Soaring

Juno Therapeutics Inc. (NASDAQ: JUNO) saw its shares skyrocket early on Wednesday after The Wall Street Journal reported that Celgene Corp. (NASDAQ: CELG) was in talks to acquire the company. ...
Read Full Story »

Canaccord Genuity Issues Top 5 Diagnostics Picks for 2018

It's a new year, and the bull market has raged on after the Dow rose 25% and the S&P 500 rose over 19% last year. 24/7 Wall St. has tracked ...
Read Full Story »

Why Eiger BioPharma Shares Are Getting Crushed

Shares of Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR) cratered on Tuesday after the firm announced that its midstage study in pulmonary arterial hypertension (PAH) did not meet its primary endpoint. As ...
Read Full Story »

Merck Wins Big With Late-Stage Lung Cancer Drug Results

Shares of Merck & Co. Inc. (NYSE: MRK) saw a handy gain on Tuesday after the pharma giant reported that its late-stage trial of Keytruda met its dual primary endpoints ...
Read Full Story »

Solid Biosciences Announces Potential Pricing for IPO

Solid Biosciences has filed an amended S-1 form with the U.S. Securities Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price its 5.89 million shares ...
Read Full Story »

How the New Tax Law Boosted UnitedHealth Earnings and Forecast

UnitedHealth Group Inc. (NYSE: UNH) reported fourth-quarter and full-year 2017 results before markets opened Tuesday. The health insurance and benefits management firm posted adjusted diluted quarterly earnings per share (EPS) ...
Read Full Story »

What to Expect From UnitedHealth Group Earnings

Before the opening bell Tuesday, Dow Jones Industrial Average component UnitedHealth Group Inc. (NYSE: UNH) is expected to report another solid quarter. After all, the company has beat analysts' earnings ...
Read Full Story »

Meet the Top Biotech Movers of This Past Week

Over the past week, a few biotech companies made absolutely massive runs, while others fell off a cliff. Although health care only kept pace with the broader markets in 2017, ...
Read Full Story »

Menlo Therapeutics Announces Potential Pricing for IPO

Menlo Therapeutics has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its 5.67 million ...
Read Full Story »

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the most recent settlement date, December 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »